Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:EWTX NASDAQ:LNTH NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.54$21.72▼$54.60$9.79B1.252.18 million shs2.09 million shsEWTXEdgewise Therapeutics$14.24-2.9%$14.04$10.60▼$38.12$1.50B0.26786,250 shs573,620 shsLNTHLantheus$52.94-3.7%$63.98$47.25▼$118.21$3.60B0.151.49 million shs842,370 shsROIVRoivant Sciences$14.08-2.3%$11.86$8.73▼$14.48$9.61B1.156.44 million shs7.59 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma0.00%-4.07%-0.21%+24.48%+95.61%EWTXEdgewise Therapeutics0.00%-8.54%+0.64%-3.00%-24.38%LNTHLantheus0.00%-3.31%-2.29%-31.97%-49.84%ROIVRoivant Sciences0.00%+8.98%+18.82%+27.08%+17.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.54$21.72▼$54.60$9.79B1.252.18 million shs2.09 million shsEWTXEdgewise Therapeutics$14.24-2.9%$14.04$10.60▼$38.12$1.50B0.26786,250 shs573,620 shsLNTHLantheus$52.94-3.7%$63.98$47.25▼$118.21$3.60B0.151.49 million shs842,370 shsROIVRoivant Sciences$14.08-2.3%$11.86$8.73▼$14.48$9.61B1.156.44 million shs7.59 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma0.00%-4.07%-0.21%+24.48%+95.61%EWTXEdgewise Therapeutics0.00%-8.54%+0.64%-3.00%-24.38%LNTHLantheus0.00%-3.31%-2.29%-31.97%-49.84%ROIVRoivant Sciences0.00%+8.98%+18.82%+27.08%+17.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9424.86% UpsideEWTXEdgewise Therapeutics 2.91Moderate Buy$40.55184.73% UpsideLNTHLantheus 2.67Moderate Buy$91.6073.03% UpsideROIVRoivant Sciences 3.50Strong Buy$17.6725.47% UpsideCurrent Analyst Ratings BreakdownLatest EWTX, ROIV, LNTH, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.009/2/2025ROIVRoivant SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight ➝ Buy$16.008/29/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.008/19/2025EWTXEdgewise TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $30.008/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/8/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$48.00 ➝ $49.008/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$112.00 ➝ $73.008/7/2025LNTHLantheusMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$120.00 ➝ $70.008/6/2025BBIOBridgeBio PharmaScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$55.00 ➝ $57.008/6/2025BBIOBridgeBio PharmaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$60.00 ➝ $61.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M44.12N/AN/A($7.71) per share-6.64EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/ALNTHLantheus$1.53B2.35$7.10 per share7.46$15.65 per share3.38ROIVRoivant Sciences$29.05M330.98N/AN/A$7.45 per share1.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)LNTHLantheus$312.44M$3.7614.088.39N/A17.82%34.06%19.10%11/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)Latest EWTX, ROIV, LNTH, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08EWTXEdgewise TherapeuticsN/A28.8728.87LNTHLantheus0.494.294.07ROIVRoivant SciencesN/A40.5440.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%EWTXEdgewise TherapeuticsN/ALNTHLantheus99.06%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%EWTXEdgewise Therapeutics23.20%LNTHLantheus2.00%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableLNTHLantheus70067.99 million66.63 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableEWTX, ROIV, LNTH, and BBIO HeadlinesRecent News About These CompaniesVivek Ramaswamy Sells $22.7 Million of Roivant Sciences StockSeptember 14 at 6:46 AM | msn.comRoivant Sciences Ltd. $ROIV Shares Bought by AmundiSeptember 13 at 3:31 AM | marketbeat.comRoivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for MosliciguatSeptember 12 at 6:31 PM | finance.yahoo.comRoivant Sciences (ROIV) Announces US$500 Million Share Repurchase Program Amid Recent ChallengesSeptember 12 at 3:49 PM | uk.finance.yahoo.comRoivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma ListSeptember 12 at 10:48 AM | markets.businessinsider.comRoivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High - Still a Buy?September 12 at 5:40 AM | marketbeat.comTeza Capital Management LLC Buys New Holdings in Roivant Sciences Ltd. $ROIVSeptember 12 at 4:53 AM | marketbeat.comRoivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma ListSeptember 11, 2025 | globenewswire.comL’action de Roivant Sciences atteint un sommet de 52 semaines à 14,29$September 11, 2025 | fr.investing.comRoivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for MosliciguatSeptember 11, 2025 | msn.comRoivant Sciences Sees Unusually Large Options Volume (NASDAQ:ROIV)September 11, 2025 | marketbeat.comWoodline Partners LP Sells 878,592 Shares of Roivant Sciences Ltd. $ROIVSeptember 11, 2025 | marketbeat.comZimmer Partners LP Boosts Position in Roivant Sciences Ltd. $ROIVSeptember 11, 2025 | marketbeat.comStock Traders Buy Large Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)September 11, 2025 | americanbankingnews.comClearline Capital LP Buys New Stake in Roivant Sciences Ltd. $ROIVSeptember 10, 2025 | marketbeat.comTwo Seas Capital LP Lowers Holdings in Roivant Sciences Ltd. $ROIVSeptember 9, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comRoivant Sciences Ltd. $ROIV Shares Sold by PointState Capital LPSeptember 8, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Buy" from BrokeragesSeptember 7, 2025 | americanbankingnews.comVivek Ramaswamy Sells 194,933 Shares of Roivant Sciences (NASDAQ:ROIV) StockSeptember 6, 2025 | insidertrades.comCutter Capital Management LP Takes $13.12 Million Position in Roivant Sciences Ltd. $ROIVSeptember 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEWTX, ROIV, LNTH, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$51.21 -1.39 (-2.64%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$52.71 +1.50 (+2.93%) As of 09/12/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Edgewise Therapeutics NASDAQ:EWTX$14.24 -0.43 (-2.93%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$15.50 +1.26 (+8.85%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Lantheus NASDAQ:LNTH$52.94 -2.05 (-3.73%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$53.08 +0.15 (+0.27%) As of 06:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Roivant Sciences NASDAQ:ROIV$14.08 -0.33 (-2.29%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$14.06 -0.02 (-0.11%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
